



## Nuno Alemān-Serrano

**Nationality:** Portuguese **Date of birth:** 15/06/1999

**Email address:** [nuno.aleman.serrano@gmail.com](mailto:nuno.aleman.serrano@gmail.com)

**LinkedIn:** <https://www.linkedin.com/in/nuno-alemān-serrano-853185171/>

### ABOUT ME

Nuno Alemān Serrano is a Medical Doctor and Invited Assistant Professor of Pharmacology at the Faculty of Medicine, University of Lisbon (FMUL). Nuno has always been fascinated by Lifesciences and Healthcare, with a special interest in Heath Systems and its Policies. Therefore, Nuno completed a Postgraduate Course in Health Consulting at the Portuguese Catholic University (UCP).

His research interests' dwell in studying the interaction between Pharmacology and Neuroscience. Nuno developed his Master Thesis in the Neuronal Communications and Synaptopathies Lab (Ana Sebastião Group) within the team of Maria José Diógenes and Alexandre de Mendonça, at the Institute of Pharmacology and Neurosciences (IFN) and Institute of Molecular Medicine João Lobo Antunes (iMM). This multidisciplinary team focuses on studying BDNF signaling dysregulation and rescue across pathologies, namely Alzheimer's disease, Epilepsy and Frontotemporal Dementia.

Nuno is also a member of the Portuguese Society for Neuroscience and Portuguese Pharmacology Society and the delegate for Portugal at the Early Career Researcher Group of EPHAR, the Federation of European Pharmacological Societies.

### WORK EXPERIENCE

#### **Medical Doctor**

[ 06/2023 – Current ]

**Country:** Portugal

#### **Invited Assistant Professor**

**University of Lisbon, Faculty of Medicine** [ 06/2023 – Current ]

**City:** Lisbon

**Country:** Portugal

Pharmacology and Neuropharmacology

#### **Researcher**

**Instituto de Medicina Molecular, iMM** [ 2020 – Current ]

**City:** Lisbon

**Country:** Portugal

Project at the Neuronal Communications and Synaptopathies Lab (Ana Sebastião Group) within the team of Maria José Diógenes and Alexandre de Mendonça, at the Institute of Pharmacology and Neurosciences (IFN) and Institute of Molecular Medicine João Lobo Antunes (iMM). Our multidisciplinary team focuses on studying BDNF signaling dysregulation and rescue across pathologies, namely Alzheimer's disease, Epilepsy and Frontotemporal Dementia.

#### **Pharmacology Teaching Assistant**

**University of Lisbon, Faculty of Medicine** [ 2020 – 2023 ]

**City:** Lisbon

**Country:** Portugal

## **Neuropharmacology Teaching Assistant**

### **University of Lisbon, Faculty of Medicine [ 2020 – 2023 ]**

City: Lisbon  
Country: Portugal

## **EDUCATION AND TRAINING**

### **Master in Medicine**

**University of Lisbon, Faculty of Medicine [ 09/2017 – 06/2023 ]**

City: Lisbon  
Country: Portugal  
Website: <https://www.medicina.ulisboa.pt>  
Field(s) of study: Health and welfare: *Medicine*  
Final grade: 17/20  
Thesis: 19/20

### **Postgraduate Course in Health Consulting**

**Portuguese Catholic University [ 02/2022 – 06/2022 ]**

City: Lisbon  
Country: Portugal  
Website: <https://www.ucp.pt/pt-pt>

### **Laboratory Animal Science**

**Champalimaud Foundation [ 2022 – 2022 ]**

City: Lisbon  
Country: Portugal  
Website: <http://www.fchampalimaud.org>

## **NETWORKS AND MEMBERSHIPS**

### **Early Career Researcher Group**

[ EPHAR, the Federation of European Pharmacological Societies, 2023 – Current ]

### **Portuguese Pharmacology Society**

[ Lisbon, Portugal, 2022 – Current ]

### **Portuguese Society for Neuroscience**

[ Lisbon, Portugal, 2022 – Current ]

## **CONFERENCES AND SEMINARS**

### **BDNF receptor dysfunction across dementias: evaluating TrkB-ICD in human AD and FTD patient samples**

[ XXV Conference of Young SIF Pharmacologists Urbino, Itália, 2023 – 2023 ]

### **BDNF receptor cleavage across dementias: TrkB-ICD in human AD and FTD patient samples**

[ 37a Reunião Anual do Grupo de Estudos de Envelhecimento Cerebral e Demência, Lisboa, 2023 – 2023 ]

### **BDNF signaling pathway dysfunction across dementias: TrkB-ICD in human AD and FTD patient samples**

[ FENS Regional Meeting, Algarve, Portugal, 2023 – 2023 ]

### **BDNF receptor cleavage across dementias: evaluating TrkB-ICD in human AD and FTD samples**

[ 2nd Symposium on Alzheimer's Disease: An Update on Pathology and Therapeutics, FEUP, Portugal, 2023 – 2023 ]

## **A new key for unlocking Alzheimer's Disease**

[ AIMS – Annual International Medical Student's Meeting, FMUL, 2022 – 2022 ]

## **Establishing a new method for TrkB-FL cleavage detection in murine CSF and plasma**

[ EpiEpiNet 2nd Annual Meeting, Lisbon, Portugal, 2023 – 2023 ]

## **BDNF receptor cleavage in Alzheimer's disease: from mice to humans**

[ 52a Reunião da Sociedade Portuguesa de Farmacologia, Porto, Portugal, 2022 – 2022 ]

## **Therapeutic monitorization of TAT-TrkB effect in preventing BDNF (TrkB-FL) receptor cleavage in CSF and blood of animal model**

[ 10a Edição do Dia da Investigação GAPIC, FMUL, Lisboa, 2021 – 2021 ]

## **Method optimization to evaluate TrkB-ICD in Cerebrospinal Fluid and Blood of mice**

[ XVII Meeting of the Portuguese Society for Neuroscience, Coimbra, Portugal, 2021 – 2021 ]

## **HONOURS AND AWARDS**

### **GAPIC Grant for Investigation Project**

GAPIC - Gabinete de Apoio À Investigação Científica, Tecnológica e Inovação [ 2021 ]

Grant for Investigation Project in Neuropharmacology

### **Portuguese Society for Neuroscience**

Travel Grant for FENS 2023 [ 2023 ]

## **LANGUAGE SKILLS**

Mother tongue(s): **Portuguese**

Other language(s):

**English**

**LISTENING C2 READING C2 WRITING C2**

**SPOKEN PRODUCTION C2 SPOKEN INTERACTION C2**

**German**

**LISTENING B1 READING B1 WRITING B1**

**SPOKEN PRODUCTION B2 SPOKEN INTERACTION B1**

**Spanish**

**LISTENING B2 READING B2 WRITING B2**

**SPOKEN PRODUCTION B2 SPOKEN INTERACTION B2**

**Latin**

**LISTENING B2 READING B2 WRITING B2**

**SPOKEN PRODUCTION B2 SPOKEN INTERACTION B2**

*Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user*